BAM
IMCR icon

Belpointe Asset Management’s Immunocore IMCR Stock Holding History

Belpointe Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-64
Closed -$3.16K – 1897
2023
Q1 		$3.16K Buy
64
+14
+28% +$787 ﹤0.01% 3177
2022
Q4 		$2.85K Buy
+50
New +$2.81K ﹤0.01% 3139

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belpointe Asset Management's IMCR Position: Q2 2023 in Review

Belpointe Asset Management sold out of Immunocore (IMCR) in Q2 2023, closing a stake of 64 shares — an estimated $3.16K sold.

Belpointe Asset Management first reported a position in IMCR in Q4 2022 and held it in 2 quarters. The position peaked at $3.16K in Q1 2023. 120 funds tracked by Wall St. Rank hold IMCR as of Q2 2023.

  • Belpointe Asset Management reported no remaining Immunocore position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 64 Immunocore shares in Q2 2023, an estimated $3.16K.
  • Belpointe Asset Management first reported a position in Immunocore in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Immunocore position peaked at $3.16K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Immunocore as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.